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Introduction. This is an open-label pilot study on four weeks of virgin coconut oil (VCO) to investigate its eﬃcacy in weight
reduction and its safety of use in 20 obese but healthy Malay volunteers. Methodology.E ﬃcacy was assessed by measuring weight
andassociatedanthropometricparametersandlipidproﬁleoneweekbeforeandoneweekafterVCOintake.Safetywasassessedby
comparingorganfunctiontestsoneweekbeforeandoneweekafterintakeofVCO.Pairedt-testwasusedtoanalyseanydiﬀerences
inallthemeasurablevariables.Results.Onlywaistcircumference(WC)wassigniﬁcantlyreducedwithameanreductionof2.86cm
or 0.97% from initial measurement (P = .02). WC reduction was only seen in males (P<. 05). There was no change in the lipid
proﬁle. There was a small reduction in creatinine and alanine transferase levels. Conclusion. VCO is eﬃcacious for WC reduction
especially in males and it is safe for use in humans.
1.Introduction
Developing countries including many Asian countries catch
up rapidly in the prevalence of obesity with higher health
risks at a lower body mass index (BMI). The latest
report from Malaysian Non-Communicable Diseases (NCD)
surveillance in 2007 demonstrated that among the adult
males, 30.9% were overweight and 13.9% were obese,
whereas among adult females, 32.4% were overweight and
18.8%wereobese(theresultswerebasedonBMI ≥25kg/m2
for overweight and BMI ≥ 30kg/m2 for obese) [1]. The
modernization of society with reduced levels of physical
activity and increased dietary intake of carbohydrate and
highly saturated fat accounted for the rapid growth in
obesity epidemic. The fat accumulating in the abdomen,
known as visceral adiposity was associated with increased
cardiovascular risk, insulin resistance, and dyslipidemia [2,
3]. Waist circumference (WC), BMI, and waist-hip ratio
(WHR) are useful surrogate anthropometric markers for
general and visceral adiposity [4–6].
Coconut (Cocos Nucifera) is commonly used in Malaysia
and other neighbouring countries including Thailand and
Philippines as a food source and its oils are used as
complementary medicine. The oil extracted from fresh
coconut meat (virgin coconut oil) contains more medium
chain fatty acids (MCFAs) (70–85%) (Table 1)c o m p a r e d
to other coconut oils [7]. MCFAs are easily oxidized lipids
and are not stored in adipose tissue unlike long chain
fatty acids (LCFAs). Thus, coconut oil containing mainly
MCFAs with little or no LCFAs may provide an ideal food
source for weight reduction [8, 9]. Furthermore, epidemi-
ologic studies coming from the African and South Paciﬁc
populations whose diets contain coconuts have revealed
no association between coconut oil ingestion and obesity
or dyslipidemia [10, 11]. Therefore, we conducted this
open label pilot study to determine the eﬃcacy of VCO
on weight reduction, anthropometric parameters, and lipid
proﬁle in obese healthy volunteers and to assess for its
safety by evaluating changes in biochemistry and organ
functions.2 ISRN Pharmacology
Table 1: Fatty acid proﬁles of virgin coconut oil.
Fatty acid proﬁle Concentration (%)
C6 Caproic 2.215
C8 Caprylic 12.984
C10 Capric 6.806
C11 Undecanoic 0.028
C12 Lauric 47.280
C13 Tridecanoic 0.030
C14 Myristic 15.803
C15 Pentadecanoic 0.006
C16 Palmitic 6.688
C16:1 Heptadecanoic 0.011
C17 Stearic 0.011
C18 Oleic 1.481
C18:1n9c Elaidic 5.073
C18:1n9t Linoleic 0.231
C18: 2n6c Linolelaidic 1.168
C18:2n6t γ-Linolenic 0.045
C18:3n6g α-Linolenic 0.007
C18:3n3a Arachidic 0.013
C20 Cis-11-Eicosenoic 0.039
C20:1n9 Behenic 0.039
C22 Cis-13,16-Docisadienoic 0.006
C24 Lignoceric 0.020
Source: Food Quality Research Unit, Universiti Kebangsaan Malaysia
(UKM), Kuala Lumpur, Malaysia.
2.MaterialsandMethods
2.1. Subjects. Free living volunteers above the age of 20 years
within the university compound (Universiti Sains Malaysia
or USM) were screened for their weight, height, body mass
index (BMI), and waist circumference (WC). Overweight
subjects were deﬁned as BMI ≥ 23kg/m2,a n do b e s es u b j e c t s
were deﬁned as BMI ≥ 25kg/m2. Abdominal obesity was
present when the waist circumference was ≥90cm for men
and ≥80cm for women. The criteria for overweight, obese,
and abdominal obesity were adapted from the Asia-Paciﬁc
report on obesity in 2000 [12]. Subjects were included
in this study if they were between the ages of 20 to 60
years old and have BMI more than 23kg/m2.E x c l u s i o n
criteria include presence of any medical or surgical illnesses,
pregnant women, those who drink any alcohol containing
beverages in any amount and previous history of intolerance
to coconut oil. The study was approved by the Human Ethics
Committee of USM.
We have screened 65 subjects over a period of 6 months
in 2008. Finally 20 subjects who agreed and satisﬁed all
inclusionandexclusioncriteriaparticipatedinthestudyafter
informed consent. The following parameters were evaluated
at “week one of study” deﬁned as one week prior to VCO
intake and again on “week six of study” deﬁned as one week
after completion of 4 weeks of VCO intake.
2.2. Anthropometric Evaluation. The body composition of
each subject including body weight, body fat percentage, fat
mass (FM), and fat-free mass (FFM) was measured with
subjects in light clothing using Tanita body composition
analyzer (Model TBF-410, Tanita Corporation). This ana-
lyzer has a maximum capacity of 200kg and a precision of
0.1kg. All the subjects were instructed to fast overnight and
to consume 250mL of plain water half an hour before the
actual measurement to ensure adequate hydration.
Heights were measured with the subjects in bare-foot
using an extendable measuring rod (Seca, Model 220/221)
with a maximum measuring length of 200-cm and a
precision of 0.1cm. WC was measured at the mid point
between the last rib and the anterior superior iliac spine
withsubjectsstandinguprightusingthesamenonextendable
measuring tape. Hip circumference (cm) was measured at
the level of greater trochanter of the femur. WHR was
calculated by dividing the waist circumference (cm) by the
hip circumference (cm) and the result presented as a ratio.
The BMI was calculated by dividing the body mass (kg) by
the square of height (m).
2.3. Dietary Evaluation. Before the study was commenced,
a 24-hour dietary recall was applied to all subjects. Food
frequency questionnaire and images depicting diﬀerent
quantitiesoffoodwereusedtoassistparticipantsinassessing
the amount of food consumed. The participants were
instructed to continue with the same pattern of diet intake
for the next 5 weeks. Participants were also advised to drink
adequate amount of water throughout the study period.
2.4. Physical Activity Evaluation. Each participant was
required to report their usual physical activities (past 1
month) before the commencement of the study. The partic-
ipants were instructed to continue with the same amount of
physical activity each day for the next ﬁve weeks.
2.5. Lipid Proﬁles. In each subject, venous blood was taken
in the morning following a 12-hour overnight fast. Triglyc-
eride (TG), total cholesterol (TC), high-density lipoprotein
(HDL), and low-density lipoprotein (LDL) were determined
intriplicateforeachsampleusingabloodchemistryanalyzer
(Model WS-ROCHE912).
2.6. Safety Evaluation. Volunteers were requested for addi-
tionalvenousbloodsamplestoassessforelectrolytes,glucose
level, renal function, and liver function. Tests for electrolytes
included sodium, potassium, calcium, phosphate, and uric
acid levels. Tests for renal function included urea and
creatinine levels. Tests for liver function included levels for
albumin, total bilirubin, aspartate transferase (AST), alanine
transferase (ALT), and alkaline phosphatase (ALP).
Of all the 20 participating subjects, only 16 subjects
had complete blood results (including electrolytes, glucose
level, renal function, and liver function tests) to assess for
safety after usage of VCO. Two subjects refused further blood
taking on week six of study, and the other two subjects had
incomplete blood results on week six of study, and were thus
excluded from analysis.ISRN Pharmacology 3
Table 2: Comparison of anthropometric measurements and lipid proﬁle values for the 20 obese volunteers at week one and week six of
study.
Parameters Week one mean
(SD)
Week six mean
(SD)
Mean diﬀerence
(SD)
95% Conﬁdence
interval
P value
Weight (kg) 82.77 (21.44) 82.53 (21.78) 0.23 (1.08) −0.27, 0.73 .35
Body mass index (kg/m2) 32.51 (5.65) 32.40 (5.69) 0.10 (0.68) −0.22, 0.42 .51
Waist circumference (cm) 102.64 (12.56) 99.78 (12.56) 2.87 (4.95) 0.55, 5.18 .02∗
Waist-Hip Ratio 0.92 (0.05) 0.91 (0.07) 0.02 (0.05) −0.01, 0.04 .13
Body fat percentage (%) 39.91 (7.16) 39.31 (6.51) 0.60 (2.87) −0.74, 1.94 .36
Fat mass (kg) 33.33 (12.64) 32.78 (12.01) 0.54 (2.72) −0.73, 1.82 .38
Fat-free mass (kg) 49.20 (12.26) 49.77 (12.28) −0.58 (2.75) −1.86, 0.71 .36
Triglyceride (mmol/L) 1.36 (0.61) 1.22 (0.41) 0.14 (0.56) −0.12, 0.40 .28
Total Cholesterol (mmol/L) 5.46 (0.85) 5.35 (0.68) 0.11 (0.74) −0.24, 0.45 .53
LDL (mmol/L) 3.33 (0.88) 3.25 (0.83) 0.08 (0.91) −0.35, 0.51 .70
HDL (mmol/L) 1.52 (0.41) 1.55 (0.41) −0.03 (0.51) −0.27, 0.21 .79
∗P value is signiﬁcant when P<. 05, SD = standard deviation.
2.7. Virgin Coconut Oil. The subjects were prescribed with
VCO 1 week after initial evaluation and continued over
the next four weeks. The VCO was sourced from a local
agricultural product company and was produced using
freeze-thawed method with no preservatives or additives
added. The oil was certiﬁed suitable for consumption by the
Malaysian Agricultural Research and Development Institute
(MS ISO 9001:2000 and MS ISO/IEC 17025 certiﬁed). The
composition proﬁle of VCO was determined by an indepen-
dent and accredited laboratory (Food Quality Research Unit,
Universiti Kebangsaan Malaysia) and is presented in Table 1.
The prescribed dosage was 30mL per day taken in three
divided doses, half an hour before each meal. Calculated
basedontheamountoflauricacidfoundinhumanmother’s
milk, the suggested daily intake of 24g of lauric acid in
an average adult is equivalent to 30mL per day of VCO
[13].Inaddition,ourearlyexperiencewithearliervolunteers
suggested that 30mL per day was a more tolerable dose
compared to higher doses without any side eﬀects.
2.8. Data and Statistical Analysis. Mean and standard devia-
tions were calculated for all numerical measurements taken
at week one and week six of study. Paired t-test analysis was
then used to test for any diﬀerences in all measured variables
at week one and week six of study with the signiﬁcance
level set at 95% conﬁdence interval (CI) and P<. 05.
To assess for possible diﬀerences between gender, measured
variables at week one and week six of study for females and
males were analysed separately and their mean diﬀerences
were calculated and compared. All statistical analyses were
performed using SPSS version 18.0 (SPSS Inc, IL, Chicago).
3. Results
The volunteers were relatively young with a mean age of
40.5 ± 8.87 years (age range between 24 to 51 years). All
subjects enrolled were of Malay ethnic origin. 20 subjects
completedthestudy,outofwhich13werefemalesand7were
males. All enrolled volunteers were obese by deﬁnition (BMI
≥ 25kg/m2) with 13 subjects having BMI above 30kg/m2.
Of these 13 subjects, 7 were males. All enrolled males had
waistcircumferenceabove90cmandallenrolledfemaleshad
w a i s tc i r c u m f e r e n c ea b o v e8 0c me x c e p tf o ro n es u b j e c tw i t h
a waist circumference of 77cm.
Theresultsforallmeasuredvariablestoassessforeﬃcacy
at week one and week six of study are presented in Table 2.
Paired t-test analysis showed that only waist circumference
was signiﬁcantly reduced after one month of VCO with a
mean reduction of 2.87 ± 4.95cm or 0.97% from initial
measurement (P = .02). All other variables showed a
nonsigniﬁcantreductionintheirmeanvaluesexceptforFFM
and HDL which showed a nonsigniﬁcant increase. The waist
circumference reduction was only signiﬁcantly seen in males
with a mean reduction of 2.61 ± 2.17cm (P = .02; 95% CI
0.61–4.62) but not in females (P = .10) even though the
reduction was larger (mean 3.00 ± 6.03cm) in females. A
subgroup analysis comparing seven males and seven females
with BMI > 30 showed that the WC reduction was seen
with males but not females (mean 2.61cm versus 1.14cm;
P = .019). When comparing seven females with BMI ≥
30 versus six females with BMI < 30, more reduction in
WC was seen in the subgroup BMI < 30 (mean reduction
4.80 ± 6.10cm versus 1.14 ± 6.20cm) but the reduction was
not statistically signiﬁcant (P = .153). The weight reduction
(mean 0.54 ± 1.38Kg) and BMI reduction (mean 0.24 ±
0.55kg/m2) were nonsigniﬁcantly higher in males when
compared to females. In addition, there were nonsigniﬁcant
increases in total cholesterol (mean 0.08 ± 0.61mmol/L),
LDL (mean 0.12 ± 0.37mmol/L), and HDL (mean 0.13 ±
0.37mmol/L) which were not seen in the females. FFM,
however, showed a nonsigniﬁcant increase in females (mean
0.93 ±3.24kg) but not in the males.4 ISRN Pharmacology
The results for all measured variables to assess for
safety after VCO consumption are presented in Table 4.
The electrolytes and glucose levels did not have signiﬁcant
changes before and after VCO consumption. The creatinine
but not urea level showed a signiﬁcant reduction after VCO
consumption (mean 6.00 ± 5.19mmol/L; P<. 001). Liver
functiontestsdidnothavesigniﬁcantchangesexceptforALT
level(mean3.06±4.40mmol/L;P = .01)whichreducedafter
VCO consumption.
4. Discussion
Coconut oil belongs to a group of vegetable oils that has
an abundance of lauric acid. A study has shown that
consumptionofsolidfatrichinlauricacidresultedinamore
favourable serum lipid proﬁle in healthy men and women
than with solid fat containing trans-fatty acids [14]. An
emerging medicinal product of importance from coconut is
virgincoconutoil(VCO)whichischeap,easilyavailable,and
widely used as over-the-counter complementary medicine
in the tropics and many foreign markets [15, 16]. Of all
diﬀerent types of coconut oils, VCO contains the highest
proportion of medium chain fatty acids, with MCFA content
being as high as 85.1% in VCO (Table 1). Hence this oil
naturally contains a mixture of MCFA and LCFA in a ratio
of 3:1. MCFAs are rapidly absorbed in the intestines even
withoutcatalyzationbythepancreaticlipaseenzyme.LCFAs,
on the other hand, required pancreatic lipase for absorption.
They are carried by the lymph to the systemic circulation in
chylomicronsandeventuallyreachtheliverwheretheyeither
undergo beta oxidation, biosynthesis to cholesterol, or are
repackaged as triglycerides. MCFAs are carried by the portal
vein to the liver where they are rapidly oxidized to energy.
Unlike LCFAs, MCFAs do not enter the cholesterol cycle and
they are not deposited in fat depots [7].
This open label pilot study attempted to ﬁnd out the
eﬃcacy of VCO on reduction of weight and anthropometric
markers of obesity in participants after 4 weeks of 30mL
in three divided doses daily VCO consumption. All the
participants in this study were instructed to continue their
normal daily diet and physical activities to minimize possible
weight reduction and change in blood lipid proﬁle which
could be attributed to reduced calorie intake or increased
energy consumption. Only WC was signiﬁcantly reduced
afterfourweeksofVCOconsumptionwithameanreduction
of 2.87±4.95cm or 0.97% reduction from baseline measure-
ment. There was a nonsigniﬁcant decrease in FM and body
fat percentage with a nonsigniﬁcant increase in FFM. This
indicated thatVCO consumption reduced body fat especially
abdominal fat since WC was signiﬁcantly decreased. The
eﬀects on triglyceride, total cholesterol, LDL, and HDL were
almost negligible indicating that VCO did not aﬀect lipid
proﬁles despite being an oil-based food source.
When the diﬀerences were analyzed according to gender,
WC was signiﬁcantly reduced in males but not in females.
This diﬀerence was still seen only in men when analyzed
in subgroups of males and females with BMI ≥ 30. The
signiﬁcant reduction in WC may be attributed to the
nonsigniﬁcant reduction in weight and BMI among the
males. This ﬁnding was important since for a given WC, the
visceral adiposity was higher in males of Asian ethnic [5, 17].
The signiﬁcant reduction of WC is considered modest given
the short duration of this study. Furthermore, all males in
the cohort are larger (BMI ≥ 30kg/m2) and therefore are
more resistant to weight loss. Few studies exist in males on
the optimal weight or BMI or WC reduction for a given
weight loss intervention. The “Gutbuster” programme in
Australia uses waist circumference as a target to encourage
weight management in men, with a target of 1% waist
reduction a week [18]. Colman et al. found that a loss of 9kg
weight reduced waist circumference by 7cm in men [19]. A
nonsigniﬁcant increase in total cholesterol, LDL, and HDL
werealsoobservedbuttheoverallincreasewastoosmall.The
eﬀects of VCO on lipid proﬁles may need a longer time to be
observed. An increase in HDL level but a reduction in total
cholesterol and LDL levels after consumption of coconut oil
was reported in experimental animals [20]. Furthermore,
the increase in LDL may be due to a diﬀerent form of
lipoprotein not associated with increase in cardiovascular
risk since there were animal studies which demonstrated that
the increase in LDL level after VCO was not associated with
aortic atherosclerosis [21].
In contrast, females exhibited diﬀerent anthropometric
proﬁles and lipid proﬁles after VCO consumption when
compared to their male counterparts. Even though the
reduction in WC was larger compared to males it was not
statistically signiﬁcant. When comparing females with BMI
≥ 30 and BMI < 30, the reduction in WC was greater
in females with BMI < 30 but it was not statistically
signiﬁcant. The larger reduction in WC was not associated
with a decrease in BMI or weight but was associated with a
nonsigniﬁcantincreaseinFFMandanonsigniﬁcantdecrease
in FM and body fat percentage. The data appeared to
indicate that females in general lose more of their body fat
with VCO and females with a lower BMI may lose more
abdominal fat. This was not reﬂected on their BMI or WHR
in contrast with their male counterparts. This supports the
evidence that diﬀerent indices are applicable to diﬀerent
gender and ethnic groups [6, 22]. However, the insigniﬁcant
reduction in WC can also be explained by the relatively
high-standard deviation suggesting that there was a high
variability of WC reduction among females who took VCO
(Table 3).Inaddition,thetotalcholesterolandLDLappeared
to decrease in females who consume VCO with triglycerides
and HDL almost unchanged. A study using coconut oil in
obese women demonstrated a reduction of abdominal fat
with unchanged lipid proﬁles providing support for similar
ﬁndings in the current study [9]. This also reﬂected that
females beneﬁted from VCO in a manner diﬀerent from
males [23, 24].
This pilot study also attempted to assess the safety
aspects of using VCO especially biochemical changes and
organ functions including the renal and liver functions.
Results have shown that all measured variables did not
demonstrate any increase from baseline but interestingly two
biochemical markers were shown to reduce after being given
VCO. These markers were creatinine and ALT levels. Animal
studies did not have any similar ﬁndings as in humans butISRN Pharmacology 5
Table 3: Comparison of mean diﬀerences in anthropometric measurements and lipid proﬁle values in 7 males and 13 females after VCO
consumption.
Parameters
Male (n = 7) Female (n = 13)
Mean diﬀerence
(SD)
95% Conﬁdence
interval P value Mean diﬀerence
(SD)
95% Conﬁdence
interval
P value
Weight (kg) 0.54 (1.38) −0.73, 1.82 .34 0.06 (0.89) −0.48, 0.60 .81
Body mass index (kg/m2) 0.24 (0.55) −0.27, 0.74 .29 0.03 (0.75) −0.42, 0.48 .89
Waist circumference (cm) 2.61 (2.17) 0.61, 4.62 .02∗ 3.00 (6.03) −0.64, 6.64 .10
Waist-Hip Ratio 0.02 (0.03) −0.01, 0.05 .14 0.02 (0.06) −0.02, 0.05 .32
Body fat percentage (%) 0.17 (1.50) −1.22, 1.56 .77 0.83 (3.42) −1.24, 2.90 .40
Fat mass (kg) 0.07 (1.47) −1.28, 1.43 .90 0.80 (3.23) −1.15, 2.75 .39
Fat-free mass (kg) 0.09 (1.49) −1.29, 1.46 .88 −0.93 (3.24) −2.89, 1.02 .32
Triglyceride (mmol/L) 0.38 (0.79) −0.35, 1.11 .25 0.01 (0.36) −0.21, 0.23 .91
Total Cholesterol (mmol/L) −0.08 (0.61) −0.65, 0.49 .74 0.21 (0.81) −0.28, 0.69 .37
LDL (mmol/L) −0.12 (0.37) −0.47, 0.22 .27 0.19 (1.10) −0.47, 0.85 .55
HDL (mmol/L) −0.13 (0.37) −0.39, 0.13 .41 0.02 (0.60) −0.34, 0.38 .90
∗P value is signiﬁcant when P<. 05, SD = standard deviation.
Table 4: Levels for electrolytes, glucose, renal function tests, and liver function tests to assess for safety in 16 volunteers at week one and
week six of study.
Parameters Week one mean
(SD)
Week six mean
(SD)
Mean diﬀerence
(SD)
95% Conﬁdence
interval
P value
Sodium (mmol/L) 138.75 140.25 −1.50 (4.62) −3.96, 0.96 .21
Potassium (mmol/L) 4.19 4.32 −0.12 (0.40) −0.34, 0.09 .23
Calcium (mmol/L) 2.34 2.31 0.03 (0.17) −0.06, 0.12 .53
Phosphate (mmol/L) 1.24 1.18 0.06 (0.21) −0.05, 0.17 .27
Uric acid (mmol/L) 276.56 257.12 19.44 (37.75) −0.68, 39.55 .06
Glucose (mmol/L) 4.58 4.40 0.18 (0.56) −0.12, 0.48 .21
Urea (mmol/L) 4.39 4.38 0.01 (1.08) −0.56, 0.59 .96
Creatinine (μmol/L) 88.62 82.62 6.00 (5.19) 3.23, 8.76 <.001
Albumin (g/dL) 44.62 44.50 0.12 (2.09) −0.99, 1.24 .80
Total bilirubin (μmol/L) 7.87 8.25 −0.37 (3.50) −2.24, 1.49 .67
AST (U/L) 21.06 19.31 1.75 (3.59) −0.16, 3.66 .07
ALT (U/L) 26.56 23.50 3.06 (4.40) 0.72, 5.41 .01
ALP (U/L) 70.19 71.19 −1.00 (6.33) −4.37, 2.37 .54
∗P value is signiﬁcant when P<. 05, SD = standard deviation.
this may have been because of the diﬀerences in the type
of coconut oil and doses used [25]. This ﬁnding in the
humans however cannot be explained and merits further
study.
There were some limitations to this study. Firstly, there
was no long-term followup on the weight, anthropometric,
and lipid proﬁle in the subjects. The full eﬀects of VCO
may not be realized without a longer duration of followup.
Even though no serious side eﬀects were reported from
the volunteers after one month of VCO consumption, a
long-term followup will be able to determine the safety of
using VCO for long periods. Secondly, the duration of VCO
consumptionwasprobablytooshortasthisisapilotstudy.A
longer period of VCO consumption may reveal more clinical
diﬀerences not shown in a short-term study. In addition, a
longer period of study can assess the tolerability of subjects
toward coconut oil. It appeared that one month of VCO
was well tolerated by all the subjects in this study. Thirdly,
the number of subjects was too small contributing to the
many nonsigniﬁcance results seen. Finally, the open-label
d e s i g na n dl a c ko fc o n t r o lg r o u pm a yi n t r o d u c eb i a st ot h e
results. Therefore, a properly designed randomized placebo-
controlled trial should be performed to further conﬁrm the
beneﬁcial eﬀects of VCO.6 ISRN Pharmacology
In conclusion, VCO is a cheap oil source containing high
concentration of MCFAs which in the current study had
shown beneﬁcial eﬀe c ti nW Cr e d u c t i o ne s p e c i a l l yi nm a l e s
without any deleterious eﬀect to the lipid proﬁle. VCO is also
safe to use for the period of study without any deleterious
eﬀects on biochemical and organ functions.
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